Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Mundipharma May Propose Sale of China Operations for $1 Billion

publication date: Aug 4, 2023

Mundipharma, an international drugmaker headquartered in Cambridge, UK, is considering selling its China operations in a deal that could be worth $1 billion. The company is owned by the Sackler family, infamous for its heavily promoted oxycodone marketing, and the sale would raise capital to help the Sacklers restructure their businesses after paying $6 billion in US fines for the opioid scandal. Two years ago, the company first floated the idea of a $1 billion deal for Mundipharma’s China business, but nothing happened. Mundipharma has operations in Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East, but not the US. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital